“SFJ has proven to be a collaborative and transparent partner from the start of our partnership. Their team is extremely knowledgeable, and add immense value well beyond the financial aspect. SFJ has remained a committed partner as we have navigated the regulatory process, with a success-driven mindset.”
— Cedric Francois, CEO
Apellis Pharmaceuticals
Lenvatinib
Eisai
Thyroid Cancer
Mylotarg
Pfizer
Myeloid
Leukemia
Inotuzumab
Pfizer
Lymphoblastic
Leukemia
Dacomitinib
Pfizer
Lung Cancer
Empaveli
Apellis
PNH
“Working with the SFJ team to design the optimal structure for Apellis was a truly collaborative effort. Together we structured a deal that was honestly transformational for Apellis and a true success for SFJ. They were creative, balancing their obligations with our needs and working with them was a pleasure. I would highly recommend.”
— Tim Sullivan, CFO
Apellis Pharmaceuticals
Apellis, a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, announced a novel, risk-sharing collaboration to support the development of APL-2 in hematologic indications with SFJ Pharmaceuticals.
PhaseBio, a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, announced a financing and co-development collaboration with SFJ to support the development of PB2452, a reversal agent for the antiplatelet therapy ticagrelor.
Nektar Therapeutics, a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cancer and auto-immune disease, announced a financing and co-development collaboration with SFJ Pharmaceuticals to support the development of Bempegaldesleukin (BEMPEG).